Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry

INTRODUCTION: Apixaban has been shown to be superior to warfarin in patients with non-valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in current guidelines. There are only scarce data about its use, efficacy, and safety in unselected patients in Germany. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeymer, Uwe, Lober, Christiane, Wolf, Andreas, Richard, Frank, Schäfer, Heinrich, Taggeselle, Jens, Kabitz, Hans-Joachim, Prondzinsky, Roland, Süselbeck, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584711/
https://www.ncbi.nlm.nih.gov/pubmed/32638266
http://dx.doi.org/10.1007/s40119-020-00188-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584711/
https://www.ncbi.nlm.nih.gov/pubmed/32638266
http://dx.doi.org/10.1007/s40119-020-00188-1

Ejemplares similares